Skip to contentpdufa.bio

IDE034 (B7H3/PTK7 bispecific TOP1 ADC)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

IDE034 (B7H3/PTK7 bispecific TOP1 ADC) is an IDEAYA Biosciences, Inc. program in solid tumors. Its next catalyst is a Readout in Q4 2027.

IDYA catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: solid tumors. Sponsor: IDEAYA Biosciences, Inc. (IDYA). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027IDYA

Specialist biotech funds holding IDYA, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Baker Bros. Advisors5,010,030$192.5 millionfiled November 16, 2026
Redmile Group381,319$14.7 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is IDE034 (B7H3/PTK7 bispecific TOP1 ADC)'s next FDA decision or readout?

The next tracked catalyst for IDE034 (B7H3/PTK7 bispecific TOP1 ADC) is a Readout in Q4 2027.

What happened at IDE034 (B7H3/PTK7 bispecific TOP1 ADC)'s most recent FDA decision?

No FDA decision for IDE034 (B7H3/PTK7 bispecific TOP1 ADC) is in our archive yet.

What is IDE034 (B7H3/PTK7 bispecific TOP1 ADC) used for?

In our records IDE034 (B7H3/PTK7 bispecific TOP1 ADC) is under review or in development for solid tumors.

Who makes IDE034 (B7H3/PTK7 bispecific TOP1 ADC)?

IDEAYA Biosciences, Inc. (IDYA).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.